COPD program decreases 30-day hospital readmission, may increase mortality

September 10, 2020

Researchers from The University of Texas Medical Branch at Galveston have found that while the 30-day readmission rate for patients with chronic obstructive pulmonary disease has decreased, the mortality rate has increased.

The UTMB researchers analyzed data from a nationwide cohort of more than 4.5 million Medicare beneficiaries with COPD to learn more about the impact of a federal program designed to reduce the number of people needing hospitalization within the first 30 days after being released from the hospital for a COPD-related illness.

The findings, said first author Daniel Puebla Neira, UTMB Pulmonary & Critical Care Fellow, are concerning in that some hospitals, in seeking to avoid financial penalties by reducing readmissions, may inadvertently affect minority and disadvantaged patients - people who may have a higher risk of dying.

The findings are currently available in the American Journal of Respiratory and Critical Care Medicine.

COPD is the third leading cause of death in the United States, affecting 12.7 million Americans and about 800,000 patients are hospitalized with COPD each year. Of these, 1 in 5 patients are readmitted after being discharged from the hospital, which is linked with poor outcomes and costs about $13 billion annually. In order to improve the patients' long-term health and control rising healthcare costs, the Patient Protection and Affordable Care Act created the Hospital Readmissions Reduction Program, or HRRP, in March 2010. The program began penalizing hospitals for higher than expected 30-day readmissions rates for non-COPD conditions.

Since the creation of the program, hospitals have reduced their readmission rates. However, it was also suspected that the program may be associated with an increase in the 30-day risk of post-discharge mortality rates for some groups of patients currently participating in the program.

"The benefits of the HRRP to improve health, prevent unnecessary hospitalizations, and control Medicare spending have been widely discussed and debated," said senior author Dr. Gulshan Sharma, director of the Division of Pulmonary Critical Care & Sleep Medicine. "An important concern is the current penalties for readmission do not to take into consideration the impact on mortality. Reducing readmissions may inadvertently affect minority and disadvantaged patients. These patients are not only at higher risk for readmission, they may also be at higher risk of dying."

The research team analyzed data from 4,587,542 Medicare fee-for-service beneficiaries with COPD who were 65 years and older. The study period from 2006 to 2017 covers the creation of HRRP and the introduction of COPD to the program. The data revealed that while the program does decrease the 30-day hospital readmission rate, it also significantly increases in the risk-standardized 30-day post-discharge mortality rates across the nation.

"Further research is needed to confirm our findings and identify factors contributing to the increased mortality seen in patients with COPD in the Centers for Medicare & Medicaid Services readmission reduction program," said Puebla Neira.
-end-
Others authors include UTMB's En Shuo Hsu, Yong-Fang Kuo and Kenneth Ottenbacher.

University of Texas Medical Branch at Galveston

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.